Therefore, the activation of caspase-1 plays an important role in inhibiting the proliferation of cancer cells, and the compounds with an activating NLRP3 inflammasome effect have the potential to be the treatments for NSCLC. The gene discussed is NLRP3; the disease is non-small cell lung carcinoma.